KIORA PHARMACEUTICALS INC (KPRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.550.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KPRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KPRX — dividend update
Dated 2026-04-07
Entry Into a Material Definitive Agreement. Private Placement On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per s…
Why it matters: Updates will show how Kiora is doing with its plans and meeting rules.
Watch forKiora announces a timeline for the global Phase 3 trial for KIO-301.
Also watch forKiora delays the Phase 3 trial or fails to secure necessary partnerships.
Why it matters: Initial data will show how well KIO-104 works for retinal inflammation. This could impact future development plans.
Supportive ifThe KLARITY trial has early data. It shows good results for retinal inflammation.
Worry ifThe KLARITY trial has early data. It shows no major activity or safety problems.
Why it matters: Completing enrollment is key for timely data readouts. It will show if demand for KIO-301 remains strong.
Supportive ifThe ABACUS-2 trial has finished enrolling participants. This helps with quick data collection.
Worry ifEnrollment in the ABACUS-2 trial is slow or much lower than expected.
Why it matters: A successful transaction could provide additional funding and expand Kiora's pipeline. This is crucial for future growth.
Supportive ifA new strategic deal was announced. It helps to diversify and grow the pipeline.
Worry ifThere are no updates or failed talks about possible strategic deals.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$156 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $471 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,640 loss on $10,000 · 36.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Initial data will show how well KIO-104 works for retinal inflammation. This could impact future development plans.
Supportive ifKiora shares early clinical data from the KLARITY trial. It shows good results for KIO-104.
Worry ifEarly data from the KLARITY trial shows little activity for KIO-104.
Why it matters: Topline data will show how well KIO-301 works for retinitis pigmentosa. This affects its future.
Supportive ifTopline data from the ABACUS-2 trial shows KIO-301 helps patients see better.
Worry ifTopline data from the ABACUS-2 trial shows no major change in vision.
Why it matters: A good safety review helps move to higher doses in the KLARITY study.
Supportive ifThe safety review shows no bad effects and allows for higher doses.
Worry ifThe safety review finds big safety problems. This stops dose increases.
Why it matters: Completing this cohort is key to understanding KIO-301's safety and effectiveness. It could lead to further enrollment.
Supportive ifKiora says it finished the higher-dose group in the ABACUS-2 trial.
Worry ifKiora stops or slows enrollment in the higher-dose group because of safety issues.
Why it matters: The data readout is crucial for Kiora's future growth. It will show if their drug development is on track.
Supportive ifInitial clinical data in Q3 2027 shows good results.
Worry ifData shows bad or unclear results.
Why it matters: The earnings report will show how the company is doing with money and health.
Watch forThe earnings report shows smaller operating losses. It also shows a better cash position.
Also watch forThe earnings report shows larger operating losses or a worse cash position.
Why it matters: Cash updates will indicate Kiora's financial health and ability to fund ongoing trials. This is critical amid ongoing losses.
Worry ifCash and short-term investments grew a lot after the earnings report.
Less concerning ifCash levels are down or not changing, which raises worries about financial health.
Why it matters: Better losses show improved capital management. This may bring in more investment.
Supportive ifOperating losses decrease further from -$2.51M in 2026-Q1.
Worry ifOperating losses worsen or remain flat compared to -$2.51M in 2026-Q1.
Why it matters: Payments from CKD will give extra money to help Kiora grow and operate.
Supportive ifKiora gets payments from CKD as KIO-301 moves forward in development.
Worry ifNo milestone payments are received from CKD due to delays in KIO-301's development.